microRNAs in Systemic Scleroderma

Patient Inclusion Criteria

• Subject aged between 18 and 75 years old, meeting the 2013 ACR/EULAR classification criteria for ScS
• Subject under an indication for the performance of esogastro-duodenal fibroscopy (FOGD), the main ones being: anemia, anorexia, weight loss, gastroesophageal reflux disease, dysphagia or odynophagia, ulcer syndrome, suspected portal hypertension
• Supported at Nice University Hospital
• Subject understands and speaks French and is able to give written consent
• Subject affiliated to Social Security or a similar scheme
• Subjects accepting additional digestive biopsies

Control inclusion criteria:

• Subject aged between 18 and 75 years old, without dysimmunitary disease
• Subject within the scope of an indication for the performance of a FOGD as defined by the treating gastroenterologist
• Subject accepting to be serologically tested for HIV and HCV
• Subject understands and speaks French and is able to give written consent
• Subject affiliated to Social Security or a similar scheme
• Subjects accepting additional digestive biopsies

Exclusion criteria

• Subject protected by law under guardianship or curatorship, or unable to participate in a clinical study under Article L. 1121-16 of the French Public Health Code
• Subject who has participated in a clinical research study in the last 3 months in which he/she was exposed to a pharmaceutical product or medical device
• Subject who has stayed in a tropical or subtropical country in the last 3 months
• Pregnant or breastfeeding participant
• Subject on a special diet for medical reasons and prescribed by a doctor or dietician (e.g. a low-calorie diet or a diet designed to lower cholesterol levels)
• Subject who regularly consumes large quantities of alcohol, i. e. more than 50 g of pure alcohol per day (e. g. more than 4 glasses of 150 ml wine, more than 4 pints of 250 ml beer, or more than 4 glasses of 40 ml containing strong alcohol)
• Subject who has used an illegal recreational drug in the past 3 months
• Subject who has taken an immunosuppressive or immunomodulatory drug (excluding corticosteroids administered at doses ≤ 10 mg/d PREDNISONE equivalent) within the previous 2 weeks, or for more than 14 consecutive days within the last 3 months
• Subject who has been vaccinated within the last 3 months
• Subject who received a blood transfusion or immunoglobulins in the last 3 months
• Subject stating that he has not been fasting for at least 10 hours
• Subject reporting HIV or HCV status
• Subject who had an infectious episode or was treated with antibiotics during the 4 weeks prior to the visit
• Subject with a positive pregnancy test
• Subject with graft versus host disease, or who has received therapy involving hematopoietic stem cells
• Subject with a severe and/or chronic and/or recurrent pathology, in particular:
• A chronic inflammatory disease of the intestine (Crohn's disease, ulcerative colitis), epidermis (psoriasis, atopic dermatitis), joints (rheumatoid arthritis), nervous system (multiple sclerosis); except ScS.
• A neurodegenerative disease
• Diabetes mellitus
• Subject who has been diagnosed with cancer and has not been in remission for more than 5 years